Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.60 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.60 |
| ▸ | RARA | P10276 | 6/20 | 0.59 |
| ▸ | RARB | P10826 | 6/20 | 0.59 |
| ▸ | RARG | P13631 | 6/20 | 0.59 |
| ▸ | RXRA | P19793 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | APP | P05067 | 3/20 | 0.59 |
| ▸ | SNCA | P37840 | 3/20 | 0.59 |
| ▸ | RXRB | P28702 | 2/20 | 0.59 |
| ▸ | RXRG | P48443 | 2/20 | 0.59 |
| ▸ | RORC | P51449 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-Ionone SCHEMBL23954 | 0.97 | CYP1A2 (0.76) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL17627827 | 0.97 | CYP1A2 (0.76) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL1867200 | 0.97 | CYP1A2 (0.76) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL23953 | 0.97 | CYP1A2 (0.76) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL29180287 | 0.95 | CYP1A2 (0.73) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL11728252 | 0.95 | CYP1A2 (0.73) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL11651364 | 0.91 | CYP1A2 (0.68) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL8367948 | 0.88 | CYP1A2 (0.64) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL8367949 | 0.88 | CYP1A2 (0.64) | CYP1A2HAO1ALDH1A1PTGS1LMNA | |
| Beta-Ionone SCHEMBL10908008 | 0.87 | CYP1A2 (0.62) | CYP1A2HAO1ALDH1A1PTGS1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3965834-B1 | USE OF A MALODOR COUNTERACTING COMPOSITION AND METHOD THEREOF | CHEMCOM SA (BE) | 2024-01-24 | — | — | EP | disclosed |
| US-11382848-B2 | Compounds reducing malodour perception and the use thereof | CHEMCOM S.A. (BE) | 2022-07-12 | — | — | US | disclosed |
| US-20220125983-A1 | MALODOR COUNTERACTING COMPOSITION AND AGENT AND THE USE THEREOF | CHEMCOM S.A. (BE) | 2022-04-28 | — | — | US | disclosed |
| EP-3573944-B1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM SA (BE) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020224754-A1 | MALODOR COUNTERACTING COMPOSITION AND AGENT AND THE USE THEREOF | CHEMCOM S.A. (BE) | 2020-11-12 | — | — | WO | disclosed |
| WO-2018138369-A1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM S.A. (BE) | 2018-08-02 | — | — | WO | disclosed |
| US-20150004126-A9 | COMPOSITIONS | GIVAUDAN S.A. (CH) | 2015-01-01 | — | — | US | disclosed |
| US-20140178326-A1 | COMPOSITIONS | GIVAUDAN S.A. (CH) | 2014-06-26 | — | — | US | disclosed |
| EP-2667901-A1 | COMPOSITIONS | Givaudan SA (CH) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101241-A1 | COMPOSITIONS | GIVAUDAN SA (CH) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382848-B2 | Compounds reducing malodour perception and the use thereof | OR51E2, OR10J3, SRD5A1 | CYP1A2 394/4885HAO1 1145/4885ALDH1A1 248/4885 |
| US-20140178326-A1 | COMPOSITIONS | ASNS, GLUL, NAALAD2 | CYP1A2 2257/4885HAO1 1427/4885ALDH1A1 819/4885 |
| US-20150004126-A9 | COMPOSITIONS | ASNS, GLUL, NAALAD2 | CYP1A2 2257/4885HAO1 1427/4885ALDH1A1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.